Xeris Pharmaceuticals (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today reported encouraging findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (“RTU”) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery. Among other highlights, results from the 12 subject, 12-week outpatient stage demonstrated that, during episodes when blood sugar was <70 mg/dL at drug dosing and without the use of glucose tabs, RTU glucagon successfully restored blood glucose levels to normal levels (blood sugar ≥70 mg/dL) within 15 minutes, at a higher frequency when compared to placebo (91% versus 73%). “We are encouraged by the results of the completed proof-of-concept PBH study. The first half of this study demonstrated the utility of liquid, stable, ready-to-use glucagon in conditions beyond rescue for severe hypoglycemia, and demonstrating safety and effectiveness in situations that require self-administration by the patient,” Xeris Chairman and CEO Paul R. Edick stated in the news release. “We believe the completed outpatient stage study further establishes the safety profile and utility for mini dosing RTU glucagon in a real-world setting. Further evaluation of RTU glucagon in PBH is warranted, especially in those who manifest blunted counterregulatory responses to hypoglycemia, and in refractory disease.” Mr. Edick continued, “We anticipate an end-of-phase 2 meeting with the FDA later this year to discuss a clinical path forward for this program.”
To view the full press release, visit http://nnw.fm/DO99o
About Xeris Pharmaceuticals, Inc.
Xeris (NASDAQ: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke(TM). Its proprietary XeriSol(TM) and XeriJect(TM) formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system. Xeris is headquartered in Chicago, IL. For more information, visit the company’s website at www.XerisPharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.